TPST Stock Summary and Trading Ideas (Tempest Therapeutics | NASDAQ:TPST)

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Tempest Therapeutics trades on the NASDAQ stock market under the symbol TPST.

As of January 7, 2026, TPST stock price declined to $2.81 with 42,362 million shares trading.

TPST has a beta of 1.56, meaning it tends to be more sensitive to market movements. TPST has a correlation of 0.05 to the broad based SPY ETF.

TPST has a market cap of $13.85 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, TPST traded as high as $127.01 and as low as $2.21.

The top ETF exchange traded funds that TPST belongs to (by Net Assets): VTI, VXF, DCOR, DFAC.

TPST has underperformed the market in the last year with a price return of -77.2% while the SPY ETF gained +17.0%. TPST has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -74.1% and -7.6%, respectively, while the SPY returned +3.0% and +0.2%, respectively.

TPST support price is $2.71 and resistance is $2.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TPST shares will trade within this expected range on the day.